Status: Recruiting
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Participants needed: 50
Trial details
Phase: Phase 2, Phase 3Age: 1-21Biological sex: AllType: InterventionalSponsor: Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyUpdated: Jan 1, 2025Locations: 1
Eligibility criteria
acute lymphoblastic, [+5]
Patients with ALL outside clinical and hematological remission [+7]